Jerome Keith R
Department of Laboratory Medicine, University of Washington Medical Center, Seattle, Washington 98195, and the Program in Infectious Diseases, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109.
Clin Appl Immunol Rev. 2005 Jan-Feb;5(1):65-76. doi: 10.1016/j.cair.2004.10.002. Epub 2005 Jan 22.
Viral diseases continue to pose some of the greatest challenges to modern medicine. For many viral diseases, prophylactic vaccines are unlikely to be developed in the near future. Fortunately, effective antiviral therapies have been developed for many of these viruses. In this review, I will focus on antiviral therapy for herpes simplex virus, human immunodeficiency virus, hepatitis C virus, and human papillomavirus. The development of compounds targeting these viruses illustrates many of the principles driving current antiviral development. It is likely that our increasing understanding of viral replication and the virus-host interaction will lead to more rapid development of new antivirals in the future.
病毒性疾病仍然是现代医学面临的一些最大挑战。对于许多病毒性疾病来说，预防性疫苗在不久的将来不太可能研制出来。幸运的是，针对其中许多病毒已经开发出了有效的抗病毒疗法。在这篇综述中，我将重点关注针对单纯疱疹病毒、人类免疫缺陷病毒、丙型肝炎病毒和人乳头瘤病毒的抗病毒疗法。针对这些病毒的化合物的研发阐明了当前抗病毒药物研发的许多原则。我们对病毒复制以及病毒与宿主相互作用的日益深入理解，很可能会在未来促使新的抗病毒药物更快地研发出来。
